|Biocryst Pharmaceuticals Inc., of Research Triangle Park, N.C.||Galidesivir||RNA polymerase inhibitor||COVID-19||Opened enrollment into placebo-controlled trial to assess the safety, clinical impact and antiviral effects|
|Cyclerion Therapeutics Inc., of Cambridge, Mass.||IW-6463||CNS-penetrant soluble guanylate cyclase stimulator||Neurodegenerative disease||Ongoing translational pharmacology study has enrolled 24 elderly subjects to evaluate safety and biomarker measures of CNS activity; top-line results expected in mid-2020|
|Cyclerion Therapeutics Inc., of Cambridge, Mass.||Olinciguat||Vascular soluble guanylate cyclase stimulator||Sickle cell disease||Closed enrollment for Strong SCD study; top-line data readout expected in third quarter of 2020|
|Astrazeneca plc, of Cambridge, U.K.||Tagrisso (osimertinib)||EGFR-targeted tyrosine kinase inhibitor||Non-small-cell lung cancer||Adaura trial in the adjuvant treatment of patients with stage IB, II and IIIA EGFR-mutated NSCLC with complete tumor resection will be unblinded early following a recommendation from the independent data monitoring committee based on its determination of overwhelming efficacy; primary endpoint was disease-free survival|
For more information about individual companies and/or products, see Cortellis.